Fig. 2
89Zr-trastuzumab binding and uptake decreases upon dasatinib treatment. Internalization and binding assays of 89Zr-trastuzumab on BT-474 and JIMT-1 cells treated with dasatinib half maximal inhibitory concentration (IC50) from 0 to 48 h showed a decrease in probe internalization and binding over time (a). Treatment and imaging scheme illustrates treatment of tumors for 7 days and/or 14 days with dasatinib followed by positron emission tomography (PET) with fluorodeoxyglucose (18F-FDG). 89Zr-trastuzumab was administered a day after with imaging acquired 48 h post injection (b). Tx, treatment; d, days